Pregnancy and Lactation

((A-278)) (A-278) Predicting FDA-Mandated Pregnancy Registries for Future Drug Approvals: Insights from the Thermo Fisher Scientific Drug & Trial Intelligence Dashboard

((A-279)) (A-279) BOOST-HP DrugScan: Identifying Medications Associated with Pregnancy Loss

((A-280)) (A-280) Like father, like child: feasibility of linking father and child in CPRD GOLD

((A-281)) (A-281) Comparison of 4 algorithms to prospectively identify pregnancies in electronic health record data

((A-282)) (A-282) Association between continued benzodiazepine use and pregnancy outcomes in women undergoing assisted reproductive technology

((A-283)) (A-283) Second-Line Antidiabetic Medications in Early Pregnancy: Do They Increase Miscarriage Risk?

((A-284)) (A-284) Nicotine Replacement Therapy in Pregnancy: A Systematic Review, Meta-Analysis, and Network Meta-Analysis of Maternal-Neonatal Outcomes and Smoking Cessation

((A-285)) (A-285) Prenatal Exposure to Antiseizure Medication and Associated Risks for Obstetrical Complications: A Population-Based Study

((A-286)) (A-286) Prenatal Exposure to Antiseizure Medications and Congenital Malformation Risk in Offspring

((A-287)) (A-287) Maternal Minoxidil Exposure and Infantile Hypertrichosis: A Global Pharmacovigilance Perspective on Dermatological Implications

((A-288)) (A-288) What to Expect when You’re Expecting Missing Outcome Data: Development of Claims-Based Algorithms for Pregnancy Identification

((A-289)) (A-289) Application of Administrative Claims-Based Algorithms to Characterize Pregnancy in Atherosclerotic Cardiovascular Disease or Likely Familial Hypercholesterolemia

((A-290)) (A-290) Self-Reported Intake of Harmful Medications During Pregnancy: Insights from 24 Years of Swedish Data

((A-291)) (A-291) Antihypertensive medication use, type of hypertension, and risk of birth defects: Expanded results from the National Birth Defects Prevention Study (1997-2011) and Birth Defects Study to Evaluate Pregnancy exposureS (2014-2021)

((A-292)) (A-292) Validation of Self-Reported Registrations on Maternal Health and Mother-Infant Outcomes: Insights from the BELpREG cohort

((A-293)) (A-293) One Problem, Multiple Solutions

((A-294)) (A-294) Ondansetron in the First Trimester of Pregnancy and Risk of Congenital Malformations: a Study using the New Zealand Pregnancy Cohort

((A-295)) (A-295) COVID-19 Vaccination Around the Time of Conception and Risk of Placenta-Mediated Adverse Pregnancy Outcomes

((A-296)) (A-296) Risk of Psychiatric Relapse After First-Trimester Antipsychotic Discontinuation in Pregnant Women with Schizophrenia

((A-297)) (A-297) Association of Risk of Congenital Malformations and Neurodevelopmental Disorders in Offspring in Women Who Continued Antipsychotics (APs) During Pregnancy

((A-298)) (A-298) Clinical Characteristics and In-Hospital Outcomes of Infective Endocarditis Among Pregnant Women with Substance Use Disorders: A Nationwide Analysis

((A-299)) (A-299) The Effect of COVID-19 During Pregnancy on Fetal Outcomes: A Propensity Score Matched Analysis using Mother-Infant Linked Claims Data

((A-300)) (A-300) Risk of Preterm Birth with Clindamycin vs. Metronidazole in Pregnant Women with Bacterial Vaginosis: A Retrospective Cohort Study

((A-301)) (A-301) Replication of the Association Between Anti-TNF Exposure During Pregnancy and Maternal and Infant Outcomes in the Dorsata Ob-GYN EMR data set and Linked Infant Data

((A-302)) (A-302) Evaluation of the Dorsata OBGYN EMR and Linked Infant Data for Use in FDA Pregnancy Safety Studies

((B-252)) (B-252) Analyzing Neonatal Mortality: A Systematic Review of Observational Study Approaches

((B-253)) (B-253) Acute fever-related infant outcomes following COVID-19 mRNA vaccination during lactation using a case-time-control design

((B-254)) (B-254) COVID-19 Vaccination During Pregnancy and Lactation and Infant Outpatient and Emergency Department Visits

((B-255)) (B-255) Comparison of depression diagnosis and treatments during pregnancy from electronic health data with self-reported information

((B-256)) (B-256) Sociodemographic Determinants and Inequities in Prenatal Healthcare in the Canadian province of Manitoba: A Population-Based Cohort Study (2010-2022)

((B-257)) (B-257) Preliminary Results from a European Post-Authorization Study to Assess the Safety of Paxlovid in Pregnancy

((B-258)) (B-258) Association between cardiac congenital malformations and mothers’ drug use during pregnancy in Catalonia, Spain

((B-259)) (B-259) Development of an Infant Outcome Tree of Congenital Anomalies across ICD Eras

((B-260)) (B-260) Development of a Pregnancy Loss Risk Score to Address Potential Confounders for Pregnancy Loss

((B-261)) (B-261) Risk of Major Congenital Anomalies in Offspring of Patients Exposed to Treatments for Bipolar Disorder During Pregnancy

((B-262)) (B-262) Risk of Developmental Delay in Offspring of Patients Exposed to Treatments for Bipolar Disorder During Pregnancy

((B-263)) (B-263) Review of Pregnancy and Lactation Use Information for Antiepileptic Medications

((B-264)) (B-264) Differential regulatory approaches to the implementation of pregnancy registries between the United States and Europe

((B-265)) (B-265) Policy Impact on Pregnancy Registry Participation and Reporting of Maternal/Infant Outcomes

((B-266)) (B-266) Landscape and Study Design Characteristics of Prospective Observational Cohort Studies on Pregnant Women in China

((B-267)) (B-267) Associations between COVID-19 vaccination during pregnancy and postpartum and human milk feeding initiation and continuation

((B-268)) (B-268) Comparative Effectiveness of Nifedipine versus Labetalol in Pregnancy for Risk of Pregnancy Loss and Preterm Birth

((B-269)) (B-269) Bias induced by method of pregnancy identification in studies of prenatal exposures using administrative healthcare data

((B-270)) (B-270) Identification of termination of pregnancy due to fetal anomaly (TOPFA) in German claims data

((B-271)) (B-271) Adverse Pregnancy and Birth Outcomes in Women with Biopsy-Proven MASLD: A Nationwide Cohort Study

((B-272)) (B-272) Mortality and Cancer in Offspring of Mothers with Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) during Pregnancy: A Nationwide Cohort Study

((B-273)) (B-273) Risk of Severe Infections in Offspring of Mothers with Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) During Pregnancy: A Nationwide Cohort Study

((B-274)) (B-274) Leveraging Complementary Study Designs to Enhance Drug Safety Assessment in Pregnancy: Benefits and Limitations

((B-275)) (B-275) Adherence to Recommended Antiviral Treatment Guidelines for COVID-19 and Influenza during Pregnancy

((B-276)) (B-276) Paternal Linkage in the PHARMO Data Network: Assessing the Impact of Paternal Drug Exposure on Child Health Outcomes

((B-277)) (B-277) Thiopurine treatment and intrahepatic cholestasis of pregnancy in pregnancies with systemic lupus erythematosus and inflammatory bowel disease - A Swedish cohort study

((B-278)) (B-278) Medication use in the pre-conceptional, pregnancy and post-pregnancy periods, with emphasis on drugs for chronic conditions. Data of the PregVal cohort, Spain (2009- 2021).

((B-279)) (B-279) The association between childhood asthma and frozen versus fresh embryo transfer in assisted reproductive technology: a nationwide retrospective cohort study using target trial emulation framework

((B-280)) (B-280) Risk of Newborn Congenital Abnormalities after Exposure to Misoprostol during Pregnancy: A Systematic Review and Meta-Analysis